ANGO vs. SPNE, ANIK, CTSO, OFIX, SRDX, ARAY, RMTI, RSLS, ABT, and ISRG
Should you be buying AngioDynamics stock or one of its competitors? The main competitors of AngioDynamics include SeaSpine (SPNE), Anika Therapeutics (ANIK), Cytosorbents (CTSO), Orthofix Medical (OFIX), Surmodics (SRDX), Accuray (ARAY), Rockwell Medical (RMTI), ReShape Lifesciences (RSLS), Abbott Laboratories (ABT), and Intuitive Surgical (ISRG). These companies are all part of the "medical" sector.
SeaSpine (NASDAQ:SPNE) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
SeaSpine has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.
In the previous week, AngioDynamics had 10 more articles in the media than SeaSpine. MarketBeat recorded 10 mentions for AngioDynamics and 0 mentions for SeaSpine. SeaSpine's average media sentiment score of 0.36 beat AngioDynamics' score of -0.11 indicating that AngioDynamics is being referred to more favorably in the news media.
SeaSpine has a net margin of -28.22% compared to SeaSpine's net margin of -60.21%. SeaSpine's return on equity of -3.48% beat AngioDynamics' return on equity.
AngioDynamics received 122 more outperform votes than SeaSpine when rated by MarketBeat users. Likewise, 60.74% of users gave AngioDynamics an outperform vote while only 56.21% of users gave SeaSpine an outperform vote.
70.8% of SeaSpine shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 9.3% of SeaSpine shares are owned by company insiders. Comparatively, 5.1% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
AngioDynamics has higher revenue and earnings than SeaSpine. SeaSpine is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
AngioDynamics has a consensus price target of $13.25, indicating a potential upside of 116.15%. Given SeaSpine's higher probable upside, analysts plainly believe AngioDynamics is more favorable than SeaSpine.
Summary
AngioDynamics beats SeaSpine on 12 of the 17 factors compared between the two stocks.
Get AngioDynamics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AngioDynamics Competitors List
Related Companies and Tools
